Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bolt Biotherapeutics, Inc.

5.13
-0.1700-3.21%
Post-market: 5.130.00000.00%17:22 EDT
Volume:4.79K
Turnover:24.68K
Market Cap:9.85M
PE:-0.19
High:5.19
Open:5.07
Low:5.06
Close:5.30
52wk High:14.36
52wk Low:4.59
Shares:1.92M
Float Shares:1.44M
Volume Ratio:0.53
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-26.4773
EPS(LYR):-33.0600
ROE:-81.33%
ROA:-33.45%
PB:0.25
PE(LYR):-0.16

Loading ...

Bolt Biotherapeutics Reports Reduced Losses and Revenue Growth

TIPRANKS
·
Aug 19

Bolt Biotherapeutics (BOLT) Gets a Buy from Lake Street

TIPRANKS
·
Aug 18

Bolt Biotherapeutics Is Maintained at Buy by Lake Street

Dow Jones
·
Aug 15

Bolt Biotherapeutics Q2 EPS $(4.46) Beats $(6.27) Estimate, Sales $1.80M Beat $819.75K Estimate

Benzinga
·
Aug 15

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 15

Bolt Biotherapeutics Inc expected to post a loss of $6.45 a share - Earnings Preview

Reuters
·
Aug 08

Bolt Metals Completes Debt Settlement to Enhance Financial Stability

TIPRANKS
·
Aug 06

Bolt Metals Announces Strategic Debt Settlement to Preserve Cash

TIPRANKS
·
Jul 28

Bolt Metals Completes Debt Settlement to Preserve Cash

TIPRANKS
·
Jun 12

Bolt Biotherapeutics Inc trading halted, news pending

TIPRANKS
·
Jun 07

BRIEF-Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025

Reuters
·
Jun 07

Bolt Biotherapeutics Announces 1-for-20 Reverse Stock Split Effective June 6, 2025

Reuters
·
Jun 05

Bolt Metals Corp. Announces Strategic Debt Settlement

TIPRANKS
·
Jun 04

Bolt Biotherapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
May 28

Bolt Biotherapeutics Initiated at Buy by Lake Street

Dow Jones
·
May 20

Cautious Hold on Bolt Biotherapeutics Amid Awaited Phase 1 Data and Strategic Decisions

TIPRANKS
·
May 17

Bolt Biotherapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
May 13

Bolt Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate

Benzinga
·
May 13

Bolt Biotherapeutics Reports 77% Drop in Q1 Collaboration Revenue, Narrows Operational Loss to $12.1 Million

Reuters
·
May 13